

# **SYNOPSIS**

03/12/2021

Review of "Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2"

**Article citation:** Kissler S, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. medRxiv 21251535 [Preprint]. 2021 Feb 19 [cited 2021 Mar 11]. Available from: <a href="https://doi.org/10.1101/2021.02.16.21251535">https://doi.org/10.1101/2021.02.16.21251535</a>

## One-minute summary

- Using modelling and longitudinal sampling, the authors tested whether acute B.1.1.7 infection is associated with higher or more sustained nasopharyngeal (NP) viral concentrations.
- A regression model was used to determine the mean duration of viral RNA shedding for B.1.1.7 (n=7) and non-B.1.1.7 (n=58) cases:
  - Proliferation phase, days (90% credible interval [CrI]): 5.3 (2.7–7.8) vs. 2.0 (0.7–3.3)
  - Clearance phase, days (90% Crl): 8.0 (6.1–9.9) vs. 6.2 (5.1–7.1)
  - Overall duration, days (90% CrI): 13.3 (10.1–16.5) vs. 8.2 (6.5–9.7)
  - Mean peak viral concentration for B.1.1.7 (n=7) and non-B.1.1.7 (n=58) cases:
    - Cycle threshold (Ct) values (90% CrI): 19.0 (15.8–22.0) vs. 20.2 (19.0–21.4)
    - Log<sub>10</sub> RNA copies/ml (90% CrI): 8.5 (7.6–9.4) vs. 8.2 (7.8–8.5)
- Based on the preliminary data, the authors concluded that B.1.1.7 may cause longer infections
  with similar peak viral concentration compared to non-B.1.1.7, potentially contributing to
  increased transmissibility.

### Additional information

- The study population represented a convenience sample including staff and players of a
  professional sports league who underwent daily Coronavirus Disease 2019 (COVID-19) testing of
  combined anterior nares and oropharyngeal swabs by real-time reverse transcription
  polymerase chain reaction (RT-PCR).
- There was an initial pool of 298 patients who tested positive by RT-PCR from November 28, 2020 to January 20, 2021. Among these, only cases with "novel" infection (i.e., likely new infection) were included in the current study. B.1.1.7 cases were identified by whole genome sequencing.
- Duration of viral proliferation and clearance were estimated by statistical modelling:

- Proliferation phase is the time from first detectable virus to peak viral concentration.
- Clearance phase is the time from peak viral concentration to initial return to the limit of detection threshold.
- Viral concentration was assumed to grow exponentially during the proliferation phase and decay exponentially during the clearance phase.

## PHO reviewer's comments

A positive RT-PCR may or may not represent the presence of live or infectious virus, as the RNA detected potentially only represents the presence of fragmented or residual viral particles. Only seven cases with the B.1.1.7 variant were included. No comparison was provided between B.1.1.7 and non-B.1.1.7 cases for other factors that may affect the period of communicability such as demographic factors (E.g., age) and clinical features (E.g., symptoms or severity). Future study should concentrate on larger sample sizes to provide generalizable findings and include detection of live virus.

### Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). Review of "Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2". Toronto, ON: Queen's Printer for Ontario; 2021.

### Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

### **Public Health Ontario**

Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit <u>publichealthontario.ca</u>.

